FBIOX - Fidelity Select Biotechnology

Nasdaq - Nasdaq Delayed Price. Currency in USD

Fidelity Select Biotechnology

Fidelity Select Portfolios82 Devonshire StreetBoston MA 02109
800-544-8544
Management Information
Rajiv Kaul,Lead Manager since October 11, 2005
Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. Prior to Fidelity, Kaul worked at Mckinsey & Company. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.
Morningstar Style Box
Yahoo partners with Morningstar a leading market research and investment data group to help investors rate and compare funds on Yahoo Finance. The Morningstar Category is shown next to the Morningstar Style Box which identifies a fund's investment focus, based on the underlying securities in the fund.
Morningstar Category
While the investment objective stated in a fund's prospectus may or may not reflect how the fund actually invests, the Morningstar category is assigned based on the underlying securities in each portfolio. Morningstar categories help investors and investment professionals make meaningful comparisons between funds. The categories make it easier to build well-diversified portfolios, assess potential risk, and identify top-performing funds. We place funds in a given category based on their portfolio statistics and compositions over the past three years. If the fund is new and has no portfolio history, we estimate where it will fall before giving it a more permanent category assignment. When necessary, we may change a category assignment based on recent changes to the portfolio.

Fund Overview

CategoryHealth
Fund FamilyFidelity Investments
Net Assets9.3B
YTD Return9.56%
Yield0.00%
Morningstar Rating★★
Inception DateDec 15, 1985

Fund Operations

Last Dividend0.00
Last Cap Gain0.00
Holdings Turnover28.00%
Average for CategoryN/A

Fees & Expenses

ExpenseFBIOXCategory Average
Annual Report Expense Ratio (net)0.74%1.31%
Prospectus Net Expense Ratio0.75%N/A
Prospectus Gross Expense Ratio0.75%N/A
Max 12b1 FeeN/AN/A
Max Front End Sales LoadN/A5.30%
Max Deferred Sales LoadN/A1.73%
3 Yr Expense Projection240N/A
5 Yr Expense Projection417N/A
10 Yr Expense Projection930N/A